VPT:CC - Ventripoint Appoints MediTek Lifesciences LLC as Distributor for California
(TheNewswire)
Toronto, Ontario – The Newswire –November 17, 2022 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) who’s mission is to improve cardiac diagnosticfor everyone, everywhere and especially for children, is pleased to announce that it has appointed MediTekLifesciences LLC. (Meditek) as a distributor for the USA-Californiamarket. MediTek distributes products specific to cardiology researchand treatment centers throughout the State of California,USA.
“It is appropriate that the first distributor in theUSA is for California, the most populous state in the USA, which is astrategic starting point for the VMS+ family of products to addressthe heart healthcare needs of the approximately 39 million residentsin the state,” commented Dr. George Adams, Ventripoint’sCEO.
California’s economy is poised to be the4 th largest in the world ( https://www.bloomberg.com/opinion/articles/2022-10-24/california-poised-to-overtake-germany-as-world-s-no-4-economy ), California has a number of leading cardiac centers and isan excellent base to begin to advance cardiac diagnostics in the USA.
MediTek has multiple sales representatives with acombined experience of over 45 years in the cardiology sector withinthe Californian market and understand how the VMS+ meets doctors’needs by providing reliable echocardiography measurements. Therepresentatives have completed training and their initial focus willbe the clinicians and cardiologists who treat patients with congenitalheart disease, which is a life-long condition where accurate regularassessments of right-heart function are critical to the planning andmonitoring of appropriate care. With an established customer base ofmore than 100 clinical sites, MediTek will grow Ventripoint’sawareness within the California market and further expand its customerbase.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2022 TheNewswire - All rights reserved.